<qa>  What is the name of the study that is open-label, fixed-dose?This is an open-label, fixed-dose study of immunization with NY-ESO-1 protein combined with CpG 7909 as adjuvant in patients with histopathologically confirmed metastatic cancer of the prostate, who have progressive disease under hormonal andor chemotherapeutic treatment duration of treatment 3 months. 